Recent advances in hepatocellular carcinoma therapy

Rinku Dutta, Ram I Mahato

Research output: Contribution to journalReview article

76 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.

Original languageEnglish (US)
Pages (from-to)106-117
Number of pages12
JournalPharmacology and Therapeutics
Volume173
DOIs
StatePublished - May 1 2017

Fingerprint

Hepatocellular Carcinoma
Therapeutics
Monoclonal Antibodies
Peptide Nucleic Acids
Peptide Initiation Factors
Peptides
Micelles
Hepatitis C
Hepatitis B
MicroRNAs
Liposomes
Alcohol Drinking
Pharmaceutical Preparations
Nanoparticles
Neoplasms
Radiotherapy
Obesity
Clinical Trials
Neoplasm Metastasis
Drug Therapy

Keywords

  • Hepatocellular carcinoma
  • drug delivery
  • miRNA
  • nanomedicines

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Recent advances in hepatocellular carcinoma therapy. / Dutta, Rinku; Mahato, Ram I.

In: Pharmacology and Therapeutics, Vol. 173, 01.05.2017, p. 106-117.

Research output: Contribution to journalReview article

@article{6a460e88405a4fe0b5c3353e149dbb50,
title = "Recent advances in hepatocellular carcinoma therapy",
abstract = "Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.",
keywords = "Hepatocellular carcinoma, drug delivery, miRNA, nanomedicines",
author = "Rinku Dutta and Mahato, {Ram I}",
year = "2017",
month = "5",
day = "1",
doi = "10.1016/j.pharmthera.2017.02.010",
language = "English (US)",
volume = "173",
pages = "106--117",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Recent advances in hepatocellular carcinoma therapy

AU - Dutta, Rinku

AU - Mahato, Ram I

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.

AB - Hepatocellular carcinoma (HCC), also called malignant hepatoma, is one of the deadliest cancers due to its complexities, reoccurrence after surgical resection, metastasis and heterogeneity. Incidence and mortality of HCC are increasing in Western countries and are expected to rise as a consequence of the obesity epidemic. Multiple factors trigger the initiation and progression of HCC including chronic alcohol consumption, viral hepatitis B and C infection, metabolic disorders and age. Although Sorafenib is the only FDA approved drug for the treatment of HCC, numerous treatment modalities such as transcatheter arterial chemoembolization/transarterial chemoembolization (TACE), radiotherapy, locoregional therapy and chemotherapy have been tested in the clinics. Polymeric nanoparticles, liposomes, and micelles carrying small molecules, proteins, peptides and nucleic acids have attracted great attention for the treatment of various cancers including HCC. Herein, we discuss the pathogenesis of HCC in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides. Synopsis of recent clinical trials of mAbs and peptide drugs has been presented with a broad overview of the pathogenesis of the disease and treatment efficacy.

KW - Hepatocellular carcinoma

KW - drug delivery

KW - miRNA

KW - nanomedicines

UR - http://www.scopus.com/inward/record.url?scp=85012930297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012930297&partnerID=8YFLogxK

U2 - 10.1016/j.pharmthera.2017.02.010

DO - 10.1016/j.pharmthera.2017.02.010

M3 - Review article

C2 - 28174094

AN - SCOPUS:85012930297

VL - 173

SP - 106

EP - 117

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

ER -